-Reuters
Ascendis Pharma’s TransCon hGH FDA Review Pushed Backed By Three Months
The FDA has extended the ongoing review of the marketing application of Ascendis Pharma A/S’s (NASDAQ:ASND) TransCon hGH (lonapegsomatropin) for the treatment…
Related Posts
Naftali Bennett of the Right-wing Yamina Party Was Sworn in Sunday as Israel’s New Prime Minister, Replacing Benjamin Netanyahu After 12 Years in Power
https://www.timesofisrael.com/liveblog-june-13-2021/
‘Arizona Marijuana Tax Revenue Exceeds $20 Million In August, State Reports’ -Marijuana Moment
https://www.marijuanamoment.net/arizona-marijuana-tax-revenue-exceeds-20-million-in-august-state-reports/
BeiGene Presents Clinical Data From 2 Phase 2 Trials Of Pamiparib At 2021 ASCO Meeting
Pamiparib, a potent and selective PARP1 and PARP2 inhibitor, demonstrated meaningful and durable efficacy in patients with advanced HER2-negative breast cancer
Pamiparib showed numerically higher progression-free